article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

The FDA Law Blog

The DCAP was an initiative launched in 2017 to remove barriers to generic drug development, approval, and market entry (see our previous post here ). Leading FDAs policy implementation of the MODERN Labeling Act , the statutory authority allowing FDA to make certain generic drug labeling updates.

FDA 141
article thumbnail

STAT+: Chick-fil-A drops a ‘No Antibiotic Ever’ pledge on chicken over supply issues

STAT

Notably, Tyson Foods, which is one of the biggest poultry suppliers, a few months ago removed the “No Antibiotics Ever” label from its chickens after reportedly encountering higher costs. Continue to STAT+ to read the full story…

Labelling 138
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk

STAT

Boger, 72, founded Vertex in 1989 and served in various roles until 2017. The clear column in his kitchen filled with racks of wine still holds a Vertex-labeled wine bottle.) He was involved in many of the turning points that led to Friday’s landmark approval, but he still finds it hard to believe.

Labelling 137
article thumbnail

Can you take trazodone and Lexapro?

The Checkup by Singlecare

Although trazodone is FDA -approved for depression, it’s primarily known for its off-label use as a sleep aid due to its sedative effects. In a 2017 systematic review , researchers concluded that low-dose trazodone is effective for insomnia in people with or without depression.

FDA 94
article thumbnail

Look out, Teva. Neurocrine's Ingrezza wins Huntington's disease FDA nod to rival Austedo

Fierce Pharma

Ingrezza was first approved in tardive dyskinesia in 2017. With its second approval, the medication’s label now largely stacks up to Teva Pharmaceuticals’ Austedo. . | The FDA approved Ingrezza capsules to treat adult with chorea associated with Huntington’s disease.

FDA 90
article thumbnail

FDA Finalizes Guidance Re Enforcement Policy for Homeopathic Drugs

The FDA Law Blog

In 2017, it decided to withdraw the compliance policy guide (CPG; from 1988) under which, for decades, the Agency essentially had permitted the marketing of over-the-counter homeopathic drug products. It issued a draft guidance in 2017 which was subsequently revised in 2019.

FDA 98
article thumbnail

Teva asks SCOTUS to overturn “skinny label” verdict on GSK drug

pharmaphorum

The case hinges around the concept of “ skinny labelling ” which was introduced to stop drugmakers extending the exclusivity period for their branded medicines – through a stream of new indications or patient populations – that can be protected with so-called “use” patents. The substance patent expired in 2007.